S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial

Ye Chen(Sichuan University), Jiyan Liu(Zhejiang University), Zhiping Li(Sichuan University), Dan Cao(Shenyang The Fourth Hospital of People), Meng Qiu(Northeast Normal University), Feng Bi(Sichuan University), Xin Wang(Harbin Medical University), Jing Wu(Shanghai Ninth People's Hospital), Qiu Li(Sichuan University), Yu Yang(Sichuan University), Yali Shen(Sichuan University), Cheng Yi(Sichuan University), Hongfeng Gou(Sichuan University), Deyun Luo(Sichuan University), Ke Cheng(Sichuan University)
The Oncologist
January 16, 2019
10.1634/theoncologist.2018-0901
Cited by 18

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
|Molecular Cancer|2021|461
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
A Comparison of Whole-Genome Shotgun-Derived Mouse Chromosome 16 and the Human Genome
|Science|2002|370
miR‐137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells
|International Journal of Cancer|2010|167